Results 81 to 90 of about 26,699 (253)

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers

Journal of the American Heart Association, EarlyView., 2021
Background Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments.
Rebecca K. Hughes, Claudia Camaioni, João B. Augusto, Kristopher Knott, Ellie Quinn, Gabriella Captur, Andreas Seraphim, George Joy, Petros Syrris, Perry M. Elliott, Saidi Mohiddin, Peter Kellman, Hui Xue, Luis R. Lopes, James C. Moon   +14 more
wiley   +1 more source

Ablation of Nonmuscle Myosin II-B and II-C Reveals a Role for Nonmuscle Myosin II in Cardiac Myocyte Karyokinesis

, 2010
Ablation of nonmuscle myosin (NM) II-A or NM II-B results in mouse embryonic lethality. Here, we report the results of ablating NM II-C as well as NM II-C/II-B together in mice.
Xuefei Ma, Siddhartha S. Jana, Mary Anne Conti, William C. Claycomb, Robert S. Adelstein, Sachiyo Kawamoto   +5 more
core   +1 more source

Up-regulating autophagy by targeting the mTOR-4EBP1 pathway: a possible mechanism for improving cardiac function in mice with experimental dilated cardiomyopathy

BMC Cardiovascular Disorders, 2020
Background Autophagy plays a crucial role in the pathological process of cardiovascular diseases. However, little is known about the pathological mechanism underlying autophagy regulation in dilated cardiomyopathy (DCM).
Bo Jin, Haiming Shi, Jun Zhu, Bangwei Wu, Quzhen Geshang   +4 more
doaj   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects

Drug Design, Development and Therapy
Hypertrophic cardiomyopathy (HCM) is a common inherited disease with substantial residual morbidity despite established pharmacological and surgical therapies. We conducted a narrative review of the current evidence on cardiac myosin inhibitors, drawing on published studies up to July 2025, including pivotal clinical trials, real-world cohorts, and ...
Hou,Lianglei, Lin,Bin, Ji,Xiaojun, Huang,Anwu   +3 more
openaire   +3 more sources

Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction

Nature Communications
Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by β-cardiac myosin ...
Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W. Schmidt, Hans-Joachim Knölker, Anne Houdusse   +8 more
doaj   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside

Interdisciplinary Medicine, EarlyView.
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione, Ana Talamillo, Juan M. Falcón‐Pérez   +2 more
wiley   +1 more source

Effect of Cardiac Myosin Inhibitors on Echocardiographic Features of Cardiac Structure and Function in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis

Reviews in Cardiovascular Medicine
Background: Recent advancements have introduced novel cardiac myosin inhibitors (CMIs) that have demonstrated significant efficacy in treating hypertrophic cardiomyopathy (HCM).
Yang Lu, Yuanyuan Zhu, Zhuang Tian
doaj   +1 more source